Endothelial dysfunction: its role in hypertensive coronary disease

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Endocrinology

Background:

• Coronary artery disease (CAD) is a leading global cause of death.
• Hypertension is a primary risk factor for CAD development.
• Endothelial dysfunction is an early, prognostically significant marker in hypertensive patients, preceding structural vascular changes.

Purpose of the Study:

• To review recent advancements in understanding hypertension-induced endothelial dysfunction.
• To explore the multifactorial pathophysiology of endothelial dysfunction in hypertension.

Main Methods:

• Review of recent scientific literature on hypertension and endothelial dysfunction.
• Analysis of mechanisms linking various conditions to endothelial dysfunction.

Main Results:

• Hyperaldosteronism and exaggerated exercise blood pressure responses contribute to endothelial dysfunction independently of high blood pressure.
• Cyclosporin-A and chronic kidney disease induce endothelial dysfunction via mechanisms including altered caveolae function and reduced nitric oxide bioavailability.
• Asymmetric dimethylarginine and 20-hydroxyeicosatetraenoic acid are implicated in endothelial dysfunction and hypertension development, particularly in postmenopausal women.
• Oral L-arginine treatment shows potential in improving endothelial function and lowering blood pressure in hypertensive individuals.

Conclusions:

• The pathophysiology of endothelial dysfunction in hypertension is complex and multifactorial.
• Recent findings deepen the understanding of endothelial dysfunction mechanisms.
• These insights support the importance of early interventions to prevent vascular and organ damage in hypertensive individuals.